Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Efpeglenatide vs Pectin: Pectin has the stronger overall evidence (5.7 vs 4.3/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Pectin wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
Shared outcomes (2)
Outcomes where both Efpeglenatide and Pectin have evidence — compare verdict strength side-by-side.
INVESTIGATIONAL — NO approved or consumer dose. In trials, efpeglenatide was given as a once-weekly subcutaneous injection, titrated up to 4-6 mg (AMPLITUDE-O used 4 and 6 mg) with gradual escalation to limit GI side effects. Not for self-administration; it is an unapproved, unmarketed investigational drug.
Once a week
Once-weekly subcutaneous injection (investigational only)
6-15g of pectin daily, split across meals with water
With main meals, With a full glass of water, Split across the day (e.g. 2-3 doses)
Powder mixed in water or food
Over ~1.8 years (trial follow-up)
Over ~1.8 years
Weeks to months
Months (titrated)
3-4 weeks
Same meal
30-120 minutes
First 1-2 weeks
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
N Engl J Med (2021) · Rct · n=4076
Pivotal randomized, placebo-controlled cardiovascular-outcomes trial (n=4,076) at 344 sites in 28 countries, in type 2 diabetes with either a history of cardiovascular disease or current kidney disease (eGFR 25.0-59.9) plus at least one other cardiovascular risk factor; weekly subcutaneous efpeglenatide 4 or 6 mg vs placebo, median follow-up 1.81 years
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
Diabetes Obes Metab (2024) · Observational · n=3983
Prespecified epidemiological analysis of AMPLITUDE-O data (n=3,983 with baseline eGFR/UACR) relating kidney-disease indices to MACE and the composite kidney outcome and testing whether efpeglenatide's effect varies with them
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.
Diabetes Care (2022) · Rct
Phase-3 double-blind, placebo-controlled monotherapy RCT in type 2 diabetes inadequately controlled with diet and exercise; once-weekly efpeglenatide 2/4/6 mg vs placebo for up to 56 weeks
Cholesterol-lowering effects of dietary fiber: a meta-analysis
The American journal of clinical nutrition (1999) · Meta analysis
Meta-analysis of 67 controlled trials directly tested pectin, oat bran, guar gum, and psyllium against blood lipids.
Metabolic and Cardiovascular Benefits of Apple and Apple-Derived Products: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Frontiers in nutrition (2022) · Systematic review
Eighteen RCTs of whole apple, apple extract, and apple juice — key dietary sources of pectin — were pooled across nine cardiometabolic outcomes.
Systematic review of the mechanisms and evidence behind the hypocholesterolaemic effects of HPMC, pectin and chitosan in animal trials
Food chemistry (2016) · Systematic review
Systematic review of animal trials examining the cholesterol-lowering mechanisms of HPMC, pectin, and chitosan.
From a meta-analysis of 67 controlled trials of soluble fibres (PMID 9925120): across 2 to 10 g a day, each gram lowered total cholesterol by 0.045 mmol/L and LDL by 0.057 mmol/L, with pectin no different from oat or psyllium fibre, so 3 g is about 0.13 mmol/L and 10 g about 0.45 mmol/L of total cholesterol. The authors call the effect small within the practical range of intake. In healthy people with normal cholesterol, 12 g of pectin a day for 4 weeks did not change cholesterol (PMID 2992264). The relationship was modelled only up to 10 g.
AI-estimated from published studies. Interpret as directional guidance.
Pectin has a higher evidence score (5.7/10 vs 4.3/10) and wins in 3 of 3 categories.
For support heart health, Pectin has a higher relevance score (72 vs 66).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.